Sandoz Group AG
SDZ | SW
Overview
Corporate Details
- ISIN(s):
- CH1243598427 (+2 more)
- LEI:
- 5493000JWK6XWFEUD320
- Country:
- Switzerland
- Address:
- Suurstoffi 14, 6343 Rotkreuz
- Website:
- https://www.sandoz.com/
- Sector:
- Human health and social work activities
- Industry:
- Hospital activities
Description
Sandoz operates in the attractive and growing global off-patent medicines market, which benefits from a growing and aging population, higher rates of chronic disease, increasing market adoption as healthcare systems and payors seek to reduce the cost of medicines, and a consistent supply of upcoming loss of exclusivities (LoEs) as patents for originator products expire. Together, these drivers are expected to support long-term growth in volumes that will more than offset anticipated erosion in price.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-11-17 07:00 |
Regulatory News Service
Sandoz launches TYRUKO (natalizumab-sztn) in US, as first and only multiple scl…
|
English | 33.9 KB | ||
| 2025-11-12 07:35 |
M&A Activity
Sandoz signs global license agreement to commercialize breast cancer biosimilar…
|
English | 22.7 KB | ||
| 2025-11-12 01:00 |
M&A Activity
Sandoz signs global license agreement to commercialize breast cancer biosimilar…
|
English | 20.1 KB | ||
| 2025-11-04 22:05 |
M&A Activity
Sandoz boosts in-house biosimilars capabilities by signing agreement to acquire…
|
English | 18.5 KB | ||
| 2025-11-04 01:00 |
M&A Activity
Sandoz boosts in-house biosimilars capabilities by signing agreement to acquire…
|
English | 15.7 KB | ||
| 2025-10-30 07:00 |
Earnings Release
Sandoz delivers a further acceleration in sales growth; full-year margin guidan…
|
English | 155.3 KB | ||
| 2025-10-30 01:00 |
Earnings Release
Sandoz delivers a further acceleration in sales growth; full-year margin guidan…
|
English | 156.9 KB | ||
| 2025-09-09 07:00 |
Legal Proceedings Report
Sandoz reaches agreement with Regeneron, resolving all patent litigation relate…
|
English | 20.4 KB | ||
| 2025-09-09 02:00 |
Legal Proceedings Report
Sandoz reaches agreement with Regeneron, resolving all patent litigation relate…
|
English | 17.1 KB | ||
| 2025-08-28 07:00 |
Regulatory News Service
Sandoz launches rivaroxaban in Germany, expanding access to high-quality antith…
|
English | 19.4 KB | ||
| 2025-08-28 02:00 |
Regulatory News Service
Sandoz launches rivaroxaban in Germany, expanding access to high-quality antith…
|
English | 17.3 KB | ||
| 2025-08-12 02:00 |
Environmental & Social Information
Sandoz launches renewable energy partnership to cover nearly 90% of electricity…
|
English | 5.5 KB | ||
| 2025-08-07 02:00 |
Earnings Release
Sandoz delivers strong H1 2025 results, with accelerated sales growth in the se…
|
English | 67.1 KB | ||
| 2025-07-01 02:00 |
Capital/Financing Update
Sandoz further asserts leadership in biosimilars, breaking ground on new Sloven…
|
English | 7.7 KB | ||
| 2025-06-02 02:00 |
Regulatory News Service
Sandoz launches first and only interchangeable denosumab biosimilars in US, pro…
|
English | 19.9 KB |
Automate Your Workflow. Get a real-time feed of all Sandoz Group AG filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Sandoz Group AG
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Sandoz Group AG via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-05-02 | N/A | Non-Executive member | Buy | None | 251,343.62 CHF |
| 2025-04-15 | N/A | Non-Executive member | Buy | None | 270,000.00 CHF |
| 2025-04-15 | N/A | Non-Executive member | Buy | None | 260,000.00 CHF |
| 2025-04-15 | N/A | Non-Executive member | Buy | None | 230,000.00 CHF |
| 2025-04-15 | N/A | Non-Executive member | Buy | None | 202,500.00 CHF |
| 2025-04-15 | N/A | Non-Executive member | Buy | None | 187,500.00 CHF |
| 2024-08-21 | N/A | Non-Executive member | Buy | None | 429,855.85 CHF |
| 2024-04-30 | N/A | Non-Executive member | Buy | None | 130,000.00 CHF |
| 2024-04-30 | N/A | Non-Executive member | Buy | None | 115,000.00 CHF |
| 2024-04-30 | N/A | Non-Executive member | Buy | None | 62,500.00 CHF |
Peer Companies
